Targets › LAMP1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Feb 2028.
Lysosomal membrane glycoprotein which plays an important role in lysosome biogenesis, lysosomal pH regulation, autophagy and cholesterol homeostasis. Acts as an important regulator of lysosomal lumen pH regulation by acting as a direct inhibitor of the proton channel TMEM175, facilitating lysosomal acidification for optimal hydrolase activity. (UniProt, P11279)
Open in Phaseline: the race on LAMP1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Immunomic Therapeutics | ITI-5000 Self-amplifying RNA vaccine targeting HERV-K and CT83 fused with LAMP-1 | HERVK, CT83, LAMP1 | Phase 1 | Triple Negative Breast Cancer (TNBC) | Feb 2028 |
Triple Negative Breast Cancer (TNBC) (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.